mick
16 years ago
part one...mddm excerpt: Our system posted a SELL-IF today. The previous BUY recommendation was issued on 12.31.2007 (2) days ago
MDM GROUP INC
Daily Commentary
Our system posted a SELL-IF today. The previous BUY recommendation was issued on 12.31.2007 (2) days ago, when the stock price was 0.0350. Since then mddm has gained 114.29% .
A bearish pattern has developed and a SELL-IF alert is issued today. The task is now to confirm the validity of this bearish pattern. We ask your effort and time. A good starting point is to keep an eye on after-hours trading and futures trading to get preliminary hints about market direction. Related news, events, economic data, and the outlook of the world markets must be closely followed prior to confirmation session.
There are three possible cases of bearish confirmation. You have to follow the session closely to see if these cases will hold or not.
The market opens with a downward gap, signaling a bearish sentiment in the first case. Your benchmark will be the opening price. If the prices stay below the benchmark, sell your shares. Any black candlestick with a downward gap is a valid bearish confirmation criterion.
In the second case, the market opens at a level, equal to or above the previous day’s close. The benchmark is that closing price. If prices during the session stay below the benchmark, sell your shares. Any black candlestick closing below the previous day’s close is the second confirmation criterion.
If, however, in both cases, the prices during the session start going over the benchmark avoid selling.
The third case of confirmation is rarely observed. The market opens with a big upward gap suggesting a very bullish day, and the day ends with a black candlestick, but still closing above the previous day’s close. Such a day satisfies the third confirmation criterion and the closing price of the black candlestick is the benchmark.
If one of the three confirmation criteria is not fulfilled, or in case of a white candlestick or a doji on the confirmation day, the SELL-IF alert remains valid, however, without confirmation and the three confirmation criteria are then sought in the following day. The only exception is the long white candlestick. Any white candlestick following a SELL-IF alert makes the signal void and invalid.
The market looks strong on the short side. So you may continue to carry the existing short positions. If the SELL-IF is confirmed, new short sale positions may be considered.
Data provided by: End of Day Data
mick
16 years ago
it has been a long time between news items. today was good.
News for M D M Group Inc (MDDM) Sector News | Topic News Sector News
Basic Materials
- Chemicals
- Energy
- Metals & Mining
Conglomerates
- Conglomerates
Consumer Goods
- Consumer Durables
- Consumer Non-Durables
- Automotive
- Food & Beverage
- Tobacco
Financial
- Banking
- Financial Services
- Insurance
- Real Estate
Healthcare
- Drugs
- Health Services
Industrial Goods
- Aerospace/Defense
- Manufacturing
- Materials & Construction
Services
- Leisure
- Media
- Retail
- Specialty Retail
- Wholesale
- Diversified Services
- Transportation
Technology
- Computer Hardware
- Computer Software & Services
- Electronics
- Telecommunications
- Internet
Utilities
- Utilities
HideMarket News
AMEX
Nasdaq
NYSE
OTCBB
Pink Sheets
Mutual Funds
Commodities
TSX
World Market News
Asia Pacific
Europe
Corporate Actions
Stock Buyback
Dividends
Earnings
Stock Splits
Insider Trading
IPO's
Business & Finance
Antitrust
Banking & Finance
Capital Gains
Mergers & Acquisitions
Economy
Consumer Price Index
Bond/Stock Update
Federal Reserve
Foreign Exchange
International Monetary Fund
Interest Rates
Hide
Mon, Dec 31, 2007
10:44 AM MDM Group Reports Progress - Marketwire
Wed, Jul 05, 2006
11:30 AM MDM Group Advises of Harrington Group's Product Positioning in China for Its OraLine Illicit Drug Test - Marketwire
Tue, Jun 06, 2006
1:03 PM MDM Group Advises of Harrington Group Financing, Executive Appointments and Next Phase Development - Marketwire
Fri, Apr 28, 2006
11:54 AM MDM Group Advises Formal Appointment of Pharmacy Distributor for OraLine in Australia by Harrington Group Limited - Marketwire
Mon, Apr 24, 2006
12:15 PM MDM Group Advises of ShockRounds Patent Filings by Harrington Group Limited - Marketwire
Tue, Mar 14, 2006
11:35 AM Bird Flu Oral Vaccine Licensed by MDM Group - Marketwire
Mon, Mar 06, 2006
11:01 AM MDM Group Retains AGORACOM Investor Relations to Expand IR Outreach - Marketwire
Tue, Dec 06, 2005
10:22 AM Harrington Settles Sun Biomedical Laboratories Acquisition and Launches New Websites - Marketwire
Tue, Oct 25, 2005
12:30 PM MDM Group Reports Progress and Sale of IT Security Patent to TIE Technologies - Marketwire
Mon, Oct 24, 2005
1:53 PM Harrington to Present SaliSystems & ShockRounds to USA Corrections Industry Conference - Marketwire
More News for MDDM More Filings for MDDM
Copyright © QuoteMedia. Data delayed 15 to 20 minutes unless otherwise indicated. RT Realtime, EOD End Of Day, PD Previous Day. Market Data powered by QuoteMedia, fundamentals by Hemscott. Terms of Use.
mick
16 years ago
MDM Group Reports Progress, Monday December 31, 10:43 am ET
VANCOUVER, BC--(MARKET WIRE)--Dec 31, 2007 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) advises that following a difficult year in which the Company's interests were specifically and deliberately excluded from participating in a Rights Issue in Sun Biomedical Limited (formerly Harrington Group) the Company has re-aligned its business interests.
Following the divesting of its interest in Sun Biomedical, MDM Group is continuing with its core business interest in the ongoing development opportunities with certain bio-defense and pharmaceutical product candidates in projects led by Dr Ed Stephen, Dr Aldar Bourinbaiar and Dr Allen Bain.
Further, in consideration of payment of AUD$500,000 the Company acquired five million shares and five million options in Zodiac Capital Limited, an investment banking group associated with Peter Boonen the Company's President and with Dr Allen Bain, also a director of MDM Group. Zodiac Capital is now listed on the National Stock Exchange in Australia following capital raisings totalling AUD$3,500,000. At current market value this Zodiac Capital shareholding is valued at approximately AUD$1,000,000.
MDM Group, through its Zodiac Capital interest, and for a nominal consideration, has also acquired five million shares in Colossal Mining Limited which is preparing for a AUD$20 million capital raising and listing on the Australian Stock Exchange in March 2008. Colossal Mining has contracted to acquire extensive iron sand deposits in the Philippines with the potential to yield in excess of a target 1.75 billion tons of iron ore. At the expected Colossal Mining IPO price the MDM Group interest is expected to be valued at approximately AUD$1,000,000.
Finally, through its Zodiac Capital shareholding, MDM Group expects to achieve further strategic shareholdings in planned future public companies to be listed through Zodiac Capital. MDM Group President Peter Boonen is the Managing Director of Zodiac Capital, Dr Allen Bain is a Director of both Companies and Zodiac Capital is chaired by Mr Robin Armstrong the Executive Director of Corporate at Findlay Securities Limited, a top 15 stockbroking business in Australia that averages over AUD$2 Billion a month in share transaction turnover.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projections and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
Contact:
For further information
Contact:
Dr Allen Bain
650-241-1888
--------------------------------------------------------------------------------
Source: MDM Group, Inc.
Email Story
Set News Alert
Print Story
ProfitScout
18 years ago
MDM Group Advises Formal Appointment of Pharmacy Distributor for OraLine in Australia by Harrington Group Limited
SANTA CLARA, CA--(MARKET WIRE)--Apr 28, 2006 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) advises that Harrington Group (Other OTC:HGRLF.PK - News), a division of MDM Group, Gold Ethicals and OTC Limited (Gold) has been appointed as the exclusive Wholesale Distributor of the OraLine drug screening products to the pharmaceutical market in Australia.
Gold is an independent and competitive pharmaceutical wholesaler and distributor headquartered in Melbourne, Australia. Gold was established in 2002 and has expanded rapidly over the past four years. It now represents in excess of 1,400 product lines and has over 1850 active pharmacy accounts.
Substance abuse is a widespread problem in our society. More than six percent of the US population over 12 years of age (13.9 million people) have used drugs within the past thirty days. Rates of use remain highest among persons aged 16 to 25, the age group entering the work force.
Gold will launch the OraLine products across Australia through national pharmacy outlets commencing late May 2006. This retail launch complements Harrington's current promotion of OraLine and other drug screening products to the workplace testing and other markets. OraLine screens simultaneously for any trace of each of the four leading drugs of abuse and will be attractively priced to retail in pharmacies at under $25.
The OraLine saliva drug screen, developed by Harrington's 40% US subsidiary Sun Biomedical Laboratories Inc, has been rated as the best in the market by many independent parties because of its ability to detect the presence of marijuana (THC) at a very low target concentration level (4ng/mL). OraLine is the only available saliva drug screen that meets this low level detection cut-off which is proposed by the US Government as a target standard for workplace screening.
The availability through Australian pharmacies of an affordable, fast, single-step drug screen that can be used in the home or workplace, will provide easy access to parents and employers to the necessary tools that can rapidly detect the recent use of the major drugs of abuse.
This press release is available on the Company's official on-line Investor Relations HUB at http://www.agoracom.com/IR/MDMGroup for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to MDDM@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. Also see www.mdmgroupinc.com.
About MDM Group Inc.
MDM Group develops strategic interests within the Security, Biodefense, Law Enforcement and Homeland Security industries. MDM Group's Biodefense Division is focused on discovery and rapid development of vaccines and other countermeasures to support the Homeland Defense and other stockpile requirements of the United States government and its citizens as well as those in other countries. MDM Group has a controlling interest in Australian listed Harrington Group which is also quoted in the US on the (Other OTC:HGRLF.PK - News).
Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
CONTACT INFORMATION
AGORA Investor Relations
http://www.agoracom.com/IR/MDMGroup
Email Contact
---------------------------------------
Source: MDM Group, Inc.
ProfitScout
18 years ago
MDM Group Advises of ShockRounds Patent Filings by Harrington Group Limited
SANTA CLARA, CA--(MARKET WIRE)--Apr 24, 2006 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) advises that Harrington Group (Other OTC:HGRLF.PK - News) today advised the Australian Stock Exchange that its New York based Patent Attorneys, Schweitzer Cornman Gross & Bondell LLP, have filed individual Patent Applications for the ShockRounds technology in the following jurisdictions: China, EU, India, Indonesia and the USA.
The patent applications seek to protect the Company's rights to the use of piezoelectric technology to produce electric charges in projectiles including less lethal munitions such as rubber bullets as well as in lethal ammunition.
The ShockRounds technology introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies. The less lethal versions of ShockRounds are intended to minimize casualties and injuries when dealing with serious crowd disturbances and threat situations.
This press release is available on the Company's official on-line Investor Relations HUB at http://www.agoracom.com/IR/MDMGroup for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to MDDM@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
About MDM Group, Inc.
MDM Group develops strategic interests within the Security, Biodefense, Law Enforcement and Homeland Security industries. MDM Group's Biodefense Division is focused on discovery and rapid development of vaccines and other countermeasures to support the Homeland Defense and other stockpile requirements of the United States government and its citizens as well as those in other countries. MDM Group has a controlling interest in Australian listed Harrington Group which is also quoted in the US on the (Other OTC:HGRLF.PK - News).
Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
Contact:
CONTACT INFORMATION
AGORA Investor Relations
http://www.agoracom.com/IR/MDMGroup
Email Contact
---------------------------------------------
Source: MDM Group, Inc.
ProfitScout
18 years ago
Bird Flu Oral Vaccine Licensed by MDM Group
License Agreement for Orally Administered H5N1 Vaccine
SANTA CLARA, CA, Mar 14, 2006 (MARKET WIRE via COMTEX) -- MDM Group, Inc. ( MDDM ) advises that its Biodefense Division has entered into an agreement with Immunitor USA Inc. to license the unique new vaccine candidate against deadly H5N1 influenza virus.
As a possible breakthrough in the development of H5N1 vaccines, Immunitor's Avian Influenza Mucosal Immunity Vaccine (Amivax) has revealed several critical advantages in studies to date:
1. orally delivered -- Amivax consists of killed influenza virus
formulated as a tablet. The vaccine is stable at room temperature and
does not lose biological activity when administered orally. This
provides a significant advantage over injected vaccines that usually
cost more, must be refrigerated and burdensome to administer.
2. acts by priming "the mucosal immunity" -- Amivax is absorbed through
the "mucosal" surface in the human gut, not directly in the
bloodstream itself, conferring immunological advantages over vaccines
that require distribution throughout the bloodstream. These advantages
may confer greater efficacy and safety of the vaccine against pathogen
that spreads primarily through the mucosal lining of the inner organs.
3. broadly active -- Amivax is expected to have a broad range of
activity against deadliest forms of influenza viruses, including H5N1
virus, an attractive feature, if the virus becomes airborne -- the
characteristic trait of pandemic virus.
4. economically and easily produced -- Amivax production to date has
been limited to research batches. However, the proprietary
manufacturing method allows the rapid scale-up to the millions of doses
at any existing vaccine facility, globally, if required.
Preliminary testing with Amivax indicates that the vaccine can confer protection against lethal virus challenge in animals. Further development work is being targeted to identification of the optimally effective dose and immunization schedule in order to select the best commercial formulation of the vaccine.
Immunitor USA Inc. is a private company based in Maryland, USA with government and/or industry alliances in Russia, Canada, Australia, China, Thailand, and the USA. As agreed between the parties, Immunitor USA Inc, will continue to direct Amivax testing and production scale-up, while MDM Group will focus on global strategic and marketing alliances to position Amivax for commercialization and deployment of the vaccine product. The license agreement prescribes a funding arrangement for the project, an opportunity for MDM Group participation in Immunitor USA equity, and a royalty payable by MDM Group to Immunitor USA on all Amivax sales and sublicensing revenues.
H5N1 influenza virus has now spread through over 39 countries in Asia, Middle East, Europe and Africa and according to the World Health Organization has already caused more than $10 billion in losses to millions of poultry farmers. The mortality rate of the virus in humans is over 50% and 170 people are reported to have caught the deadly virus. Amivax and other H5N1 vaccines are now being developed worldwide to prevent the eventual pandemic that may occur if H5N1 virus mutates into a form that is easily transmissible among humans. A vaccine such as Amivax may prevent infection, or even substantially lessen symptoms of infection or mortality when given shortly after exposure to virus.
This press release is available on the Company's official on-line Investor Relations HUB at http://www.agoracom.com/IR/MDMGroup for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to MDDM@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
About Immunitor USA Inc.
Immunitor USA Inc., (Company) was incorporated in February 2004 in Maryland, USA as licensee of Immunitor Corporation Co., Ltd. -- the first private biotech company founded in Thailand in 2001. The Company has the exclusive rights to patents owned by Thai partner who has developed and currently manufactures four vaccines as means of preventing and/or treating viral (V1), bacterial (V2), and fungal (V4) infections; and cancer (V3). The licensed technology is unique since it enables the formulation of any protein or vaccine (recombinant or from natural source) as an oral pill, which is easy to administer, has low manufacturing cost and is stable, safe, and effective. No other technology is believed to exist that could compete with Immunitor's breakthrough invention which is forecast to reshape the vaccine and therapeutic protein industry. Company's private clinic and manufacturing plant (which has to date produced over 12M doses) are both based in Thailand. Immunitor has developed the oral H5N1 bird flu vaccine candidate that is licensed to MDM Group.
About MDM Group Inc.
MDM Group's Biodefense Division is focused on discovery and rapid development of vaccines and other countermeasures to support the Homeland Defense and other stockpile requirements of the United States government and its citizens as well as those in other countries. MDM Group's overall business interests are focused on the Security, Biodefense and Homeland Security industries.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
MDM Group is featured on www.agoracom.com and for further information see: www.mdmgroupinc.com or:
Contact MDM Group Investor Relations at:
AGORACOM Investor Relations
http://www.agoracom.com/IR/MDMGroup
Contact via http://www.marketwire.com/mw/emailprcntct?id=AA951AFCB74854EB
SOURCE: MDM Group, Inc
http://www.agoracom.com/IR/MDMGroup
Copyright 2006 Market Wire, All rights reserved.
Golden Cross
18 years ago
MDDM: MDM Group Retains AGORACOM Investor Relations to Expand IR Outreach
Monday March 6, 11:01 am ET
SANTA CLARA, CA--(MARKET WIRE)--Mar 6, 2006 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) today announced it has retained AGORACOM Investor Relations Corp. (AGORACOM) (http://www.agoracom.com) to provide additional investor relations outreach.
The goal is to create expanded communication between MDM Group, its shareholders and the investment community through AGORACOM's Internet-based investor relations system. Effective immediately, a customized and monitored MDM Group IR HUB (http://www.agoracom.com/IR/MDMGroup) will allow both MDM Group and AGORACOM to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications. The IR HUB will also provide one-click access to the MDM Group broker fact sheet, company profile, the five most recent press releases, email list registration, the latest stock quote & chart information, and an executive audio address by MDM Group officers discussing important matters.
ADVERTISEMENT
In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the Company that is free of spam, bashing, hyping and profanity.
The consolidation of these activities will save management considerable time, effort and expense, allowing greater focus on core business operations, while significantly improving shareholder communications.
MDM Group Executive Chairman and CEO, Peter Boonen stated, "The significant amount of business achievements announced by MDM Group is proof positive that we have reached true commercial acceptance of our capabilities. As such, we believe the time has now come to significantly increase our communications with shareholders and the investment community. The solution provided by AGORACOM helps our need to manage and execute an IR strategy in a cost efficient manner, while providing our management team with the ability to focus on executing the business plan. Our shareholders and Company will benefit greatly from near real-time communications, the creation of a true MDM Group shareholder community, and increased exposure."
Investors can visit the MDM Group IR Hub at http://www.agoracom.com/IR/MDMGroup where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to email all questions and correspondence to MDDM@agoracom.com where they can also request addition to the investor email list to receive all future press releases and updates in real time.
About AGORACOM Investor Relations Corp. http://www.agoracom.com http://www.AgoraIR.com
bartermania
19 years ago
MDM Group Reports Progress and Sale of IT Security Patent to TIE Technologies
Tuesday October 25, 12:29 pm ET
SANTA CLARA, CA--(MARKET WIRE)--Oct 25, 2005 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) advises the following as a general update of progress and development within the Company:
MDM Group has been extremely busy with its corporate, business and opportunity development over the past several years and specifically over the last eighteen months. Over this period MDM Group has:
Successfully spun out the ShockRounds development into the Australian listed Harrington Group Limited (Other OTC:HGRLF.PK - News) or (Australia:HGR.AX - News). Harrington has subsequently announced agreement to acquire Sun Biomedical Laboratories, a business that markets leading saliva and urine illicit drug testing products including OraLine® globally. The company expects a number of significant marketing programs to be initiated over the coming months and will advise the market accordingly as these efforts progress.
Successfully test-fired ShockRounds prototypes and announced agreement to use the first production product in 10 - 12 US corrections center beta sites.
ShockRounds development is progressing solidly and is soon expected to be even better positioned through the integration of complimentary less-lethal technology. In addition announcement of significant global partner relationships will be made as and when they become material.
Established working relationships with Russia's leading scientific research centers through our partnerships and associations with the Russian Biotechnological Consortium for Medicine and Agriculture (BIOMAC) and with the International Science and Technology Center (ISTC).
Under the leadership of our Vice President Biodefense Development, Ed Stephen, MDM has established collaborations that span the globe and deal with potential product candidates for several agents considered to be on the top of the bioterrorism threat list as well for viruses that may result in global pandemics such as the widely reported H5N1 strain of avian flu. MDM is also evaluating product candidates for diseases caused by such agents including smallpox virus and anthrax. These product candidates represent the two primary types of products in development against biothreats: Vaccines, which stimulate the body to build its own immunity, and Pharmaceuticals, which often work immediately and independently of the body's immune system. Pharmaceutical drugs that are effective against one threat agent often are effective against several similar threat agents, so-called "broad spectrum" agents.
MDM's current vaccine development project targets the smallpox virus, an agent that is at the top of the bio-warfare bio-terrorism threat list of many agencies worldwide. The advantage of MDM's vaccine approach is that the vaccine product will likely address a large number of variants of the target virus. A similar approach to development of a vaccine is under consideration for influenza, in particular the H5N1 virus and variants.
The MDM biodefense division also puts particular emphasis on projects that involve existing drugs, or agents for which there already exists clinical safety data. Such product candidates allow rapid product development. MDM is in advanced evaluation stages of several such product candidates and will report its progress in due course.
MDM also, following a protracted legal action, successfully retained the full title and ownership of an Identity and Security patent that secures Internet and Network data and or communications using identifier or access codes of 25 or more bytes or characters. MDM has agreed to vend this asset into TIE Technologies an affiliated company (Other OTC:TIET.PK - News) in which MDM will have an approximate 65% ownership and control whilst still retaining a 4% royalty over revenues generated through patent protected income streams. TIE Technologies is further in process of completing a number of additional commercial relationships that will be reported when they materialize.
MDM is involved in a number of further developments that will continue to expand the Company's global reach and continue to strengthen its asset base. MDM will foster this progress with the ultimate objective to gain further interest in listed companies that it will have significant and/or controlling interests in. These companies will be independent and be self funded with their own, although controlled, management structures.
Most importantly MDM throughout the group interests has assembled a solid management and advisory team that together, with our partners and associates, the Company is very proud and appreciative of. Their contribution to the ongoing development of the Company cannot be underestimated as they are an integral part of the real capital value of the Company. In general terms MDM has a team of world class scientists, IT specialists with top clearance, as well as advisors to government.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
MDM Group and Harrington Group feature on www.Homelanddefensestocks.com a global investment research portal for defense and security.
Contact:
For further information see: http://www.mdmgroupinc.com or contact:
MDM Group Investor Relations
Steve Weitzman
1-888-573-2306
--------------------------------------------------------------------------------
Source: MDM Group, Inc
bartermania
19 years ago
Harrington to Present SaliSystems & ShockRounds to USA Corrections Industry Conference
Monday October 24, 1:53 pm ET
Weekend Prison Drug Raids in WA Highlight Drug Problems in Australian Jails
SANTA CLARA, CA--(MARKET WIRE)--Oct 24, 2005 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) company Harrington Group Limited (Other OTC:HGRLF.PK - News) and (ASC: HGR) earlier today advised the Australian Stock Exchange that Harrington Group CEO, Marshall Couper, has been invited to present the company's SaliSystems illicit drug screening product -- OraLine -- and the less lethal ShockRounds "electric" bullet technology to the US corrections industry at the CERT-Ops Conference in Washington DC on 31 October and 1 November, 2005. (www.certops.com).
Mr. Couper will introduce the Company's products for use in the prison system and for use by Correctional Emergency Response Team (CERT) operators.
The conference is put on by the CERT Council of 100 which was established by the US Correctional Tactical Officers Association (CTOA) to facilitate corrections counter-terrorism information globally and endorse accredited industry products, services and standards. The CERT Council is made of 24 CERT Senior Commander/Senior Team Leaders and 12 permanent Council members from around the world including Australia with 12 members rotating a Council seat.
The CERT conference is restricted to senior decision makers that are actively looking at ways to increase their officers' safety. Drug use in prisons is an increasing problem around the world and presents serious risks to prison officers and CERT teams. In the US, where around 3,000,000 people are incarcerated, and 60% of the world's supply of illicit drugs are consumed, the problem is rife and directly impacts upon the safety of prison officers.
Company MD, Peter Boonen stated: "This closed industry conference represents an ideal forum for the company to directly showcase our SaliSystems saliva drug tests and our ShockRounds technology to the select high level decision makers attending and representing over 30,000 CERT operators. Industry introductions such as through this CERT-Ops conference give the Company North American and global introduction to potential major markets."
The illicit drug use problem in Australian prisons was highlighted through a drug raid on visitors to WA's Hakea and Casuarina prisons over the weekend with the media reporting that drugs, including cannabis, amphetamines and other pills, were found on visitors and in their vehicles including one woman having four balloons filled with cannabis. WA Justice Minister, John D'orazio, is reported as stating: "Stopping illegal drug use will make jails safer for prison staff and may help some offenders break established habits."
ABOUT HARRINGTON GROUP LIMITED
Harrington Group is a developer of homeland security and law enforcement products and solutions including its ShockRounds(TM) "electric" bullet technology which is positioned as a major breakthrough in less lethal products for the corrections, law enforcement, military and homeland security industries. Harrington Group has entered into a conditional agreement to acquire 40% of Sun Biomedical Laboratories Inc. for 12 million shares and has an option to 30 June, 2006 to acquire the remaining 60%. The total value of the agreement to acquire, Sun Biomedical, the developer of the SaliSystems illicit drug testing products, is AUD$3.7 million.
To see copy of the Company's full Australian Stock Exchange releases and associated media releases see www.hgrltd.com.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
MDM Group and Harrington Group are featured on www.Homelanddefensestocks.com a global investment research portal for defense and security.
Contact:
For further information see:
http://www.mdmgroupinc.com
http://www.hgrltd.com
Or contact:
Harrington Group (US) and MDM Group Investor Relations
Steve Weitzman
1-888-573-2306
bartermania
19 years ago
Harrington Media Release and Coverage
SANTA CLARA, CA, Oct 05, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) company Harrington Group Limited (OTC: HGRLF) and (ASX: HGR) advises of its Media Release in Australia earlier today concerning its new drug testing interests following the recent agreement to acquire Sun Biomedical Laboratories, Inc. The Release can be accessed at www.hgrltd.com
The Company also received coverage in the Bulletin which is acknowledged as one of Australia's oldest and most prestigious news titles. The Bulletin is also available online and offers news, features, politics, business, investing and can be accessed at http://bulletin.ninemsn.com.au/ then scroll down and click on "The Speculator" for the article.
Further, the Company advises that it is an exhibitor and introducing the illicit drug testing products to the Australian Police Summit being held in Melbourne, Australia commencing today. See: www.policesummit.com/melbourne/
It should be noted that it was first intended and announced for MDM Group to acquire the Sun Biomedical Laboratories interest. This is not proceeding as MDM Group will now have its interest through its shareholding in Harrington Group which is better positioned to market the products due to its already established industry database, especially in the law enforcement, corrections and military market sectors.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
MDM Group and Harrington Group are featured on www.Homelanddefensestocks.com a global investment research portal for defense and security.
For further information see: www.mdmgroupinc.com or www.hgrltd.com
Contact:
Harrington Group (US) and MDM Group Investor Relations
Steve Weitzman
1-888-573-2306
SOURCE: Harrington Group Ltd
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Aerospace and Defense:Weapons
Government:Security (law enforcement, homeland etc)
bartermania
19 years ago
Development Partnership With Materials Systems Inc
Harrington Group Ltd (OTC: HGRLF) (ASX: HGR), an emerging leader in next-generation less-lethal weapons solutions for the military and law enforcement, and Materials Systems Inc (MSI) of Boston, MA, USA, advise that they have commenced a development partnership to explore the expansion of potential options and materials for the existing ShockRounds(TM) line of products.
Using MSI expertise and patented technology, the Company will be aiming at complementing ShockRounds product development to date with materials more suited for use in smaller calibers than the 37mm and 40mm currently under development. This will enable a far improved power to weight ratio within each projectile.
Harrington Group CEO Marshall Couper stated, "We welcome MSI as a Harrington Group development partner and look forward to gaining the full benefit of their track record in development, optimization and fabrication. We anticipate that the MSI partnering will enable us to expand our product range and the effectiveness of ShockRounds products."
Similarly, Materials Systems President Les Bowen outlined his enthusiasm for this development partnership: "We have been in discussions with Harrington Group for some time and are very excited about this effort and its market potential. MSI has been on the leading edge of research and development with these materials and this project is a natural extension of our expertise and core engineering skills."
ABOUT HARRINGTON GROUP LIMITED
Harrington Group Limited, an MDM Group (OTC: MDDM) company listed in Australia and quoted in the US, is a developer of homeland security, military and law enforcement products and solutions including its ShockRounds technology, which is positioned as a major breakthrough in the ammunition, military and law enforcement industries. This patent-pending ShockRounds technology introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies. The less lethal versions of ShockRounds are intended to minimize casualties and injuries when dealing with serious crowd disturbances and threat situations.
ABOUT MATERIALS SYSTEMS INC
Founded in 1991, Materials Systems Inc (MSI) develops and manufactures advanced materials, custom components and specialised piezoceramics for the US Navy, defense and commercial systems customers. Its products range from acoustic transducers for underwater sonar and industrial ultrasound to large sapphire windows for transparent armor and infrared surveillance. See: www.matsysinc.com
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
Source: Market Wire (September 22, 2005 - 9:10 AM EDT)
News by QuoteMedia
www.quotemedia.com
ProfitScout
19 years ago
United States Corrections Special Operations Group (US C-SOG) Advises That ShockRounds(TM) Is a Powerful New Tool That Will Prove Immensely Useful in Protecting Officers and Reducing Fatalities
SANTA CLARA, CA, Sep 20, 2005 (MARKET WIRE via COMTEX) -- Following advice yesterday of a strategic Partnership Agreement with US C-SOG and the CERT Tactical Network, MDM Group (OTC: MDDM) company, Harrington Group Ltd (OTC: HGRLF) (ASX: HGR), today further advised the Australian Stock Exchange that under the terms of the agreement, US C-SOG will work closely with Harrington's product development team to finalize the development of safe less-lethal products for the Corrections Emergency Response Team (CERT) community. US C-SOG will also handle worldwide corrections personnel training and tactical development for the ShockRounds products. See: http://www.uscsog.com and http://www.certops.com.
"For too long, when it comes to less-lethal technology, CERT operators have had a limited range of options," said Senior Team Leader Joseph Garcia of US C-SOG. "ShockRounds will prove immensely useful in protecting our officers and reducing fatalities among inmates. Quite simply, ShockRounds gives CERT operators a powerful new tool to deal with the threats they confront every day."
Marshall Couper, CEO of Harrington Group, stated: "We are very pleased to be working with US C-SOG who will provide a direct channel to market for Harrington in the corrections market. Their strong relationships with over 4,000 corrections facilities in 14 countries and access to many more through the CERT Tactical Network will help facilitate our transition into this market with our highly anticipated less-lethal products. We are also excited by the prospect of beta-testing the ShockRounds products through our relationship with US C-SOG."
ABOUT HARRINGTON GROUP LIMITED
Harrington Group Limited is a developer of homeland security, military and law enforcement products and solutions including its ShockRounds technology which is positioned as a major breakthrough in the ammunition, military and law enforcement industries. This patent-pending ShockRounds technology introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies. The less-lethal versions of ShockRounds are intended to minimize casualties and injuries when dealing with serious crowd disturbances and threat situations.
ABOUT US C-SOG
US Correctional-Special Operations Group (US C-SOG) is the only full-service corrections training firm in the United States specializing exclusively in Correctional Tactical Operations. US C-SOG's training offers intense, cutting-edge techniques and real-world operational training tactics. US C-SOG is one of the three pillars of the CERT Tactical Network. For more information see www.uscsog.com.
ABOUT CERT TACTICAL NETWORK
The CERT Tactical Network is the international network of Correctional Emergency Response Team operators representing some 30,000 special operations officers in more than 7,000 correctional institutions worldwide. These specially trained emergency response officers are charged with the most dangerous jobs in the corrections industry, including transport of violent prisoners and the quelling of riots and other disturbances. For more information see www.certops.com.
MDM Group is featured on www.Homelanddefensestocks.com, a global investment research portal for defense and security.
For further information http://www.mdmgroupinc.com or http://www.hgrltd.com
or contact:
MDM Group, Inc.
Steve Weitzman
212-334-9300 Ext. 11
SOURCE: MDM Group, Inc.
CONTACT: http://www.mdmgroupinc.com
http://www.hgrltd.com
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Aerospace and Defense:Weapons
Government:Security (law enforcement, homeland etc)
bartermania
19 years ago
United States Corrections Special Operations Group (US C-SOG) Enters Into Strategic Partnership With Harrington Group
US C-SOG Endorses ShockRounds(TM)
SANTA CLARA, CA, Sep 19, 2005 (MARKET WIRE via COMTEX) -- As announced today by US C-SOG and The CERT Tactical Network, MDM Group (OTC: MDDM) company Harrington Group Ltd (OTC: HGRLF) (or Australia "HGR") has signed a Strategic Partnership Agreement with the leading US correctional consulting group to facilitate the deployment of its ShockRounds technology for use by emergency response teams at correctional facilities around the world. See: www.uscsog.com and www.certops.com.
Harrington Group Ltd. has entered into a strategic partnership with United States Corrections - Special Operations Group (US C-SOG) to promote Harrington's ShockRounds technology to the corrections industry. US C-SOG, in conjunction with Harrington Group Management, will also establish a beta testing program with at least ten county, state, federal and overseas prisons as beta-testing sites for the new ShockRounds less lethal products.
ABOUT HARRINGTON GROUP LIMITED
Harrington Group Limited is a developer of homeland security, military and law enforcement products and solutions including its ShockRounds technology which is positioned as a major breakthrough in the ammunition, military and law enforcement industries. This patent-pending ShockRounds technology introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies. The less lethal versions of ShockRounds are intended to minimize casualties and injuries when dealing with serious crowd disturbances and threat situations.
ABOUT US C-SOG
US Correctional-Special Operations Group (US C-SOG) is the only full service corrections training firm in the United States specializing exclusively in Correctional Tactical Operations. US C-SOG's training offers intense, cutting-edge techniques and real-world operational training tactics. US C-SOG is one of the three pillars of the CERT Tactical Network. For more information, see www.uscsog.com.
ABOUT CERT TACTICAL NETWORK
The CERT Tactical Network is the international network of Correctional Emergency Response Team operators representing some 30,000 special operations officers in more than 7,000 correctional institutions worldwide. These specially trained emergency response officers are charged with the most dangerous jobs in the corrections industry, including transport of violent prisoners and the quelling of riots and other disturbances. For more information, see www.certops.com.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
For further information, www.mdmgroupinc.com or www.hgrltd.com or contact:
MDM Group, Inc.
Steve Weitzman
212-334-9300 Ext. 11
SOURCE: MDM Group, Inc
Copyright 2005 Market Wire, All rights reserved.
ProfitScout
19 years ago
Smallpox Vaccine Development Agreement
SANTA CLARA, CA, Aug 09, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that its Biodefense Division has entered into agreement with AvaxisBio for the development of a smallpox vaccine designed for safe and effective public immunization to counter bioterrorism. AvaxisBio is developing a vaccine by rational design, made from small peptide molecules based on selected portions of the Variola virus genome selected for optimal effects on the human immune system.
Smallpox is a top priority on the bioterrorism threat list. Since routine vaccinations stopped in 1980 and vaccination offers immunity for only seven to ten years, the world is in effect a virgin population, highly susceptible to reintroduction of the virus. Although the official repositories of the virus are maintained under high security in the United States and Russia, there is concern that terrorists may have access to certain smallpox virus and could use it as a weapon. If this happened, a large percentage of the population could become seriously ill as smallpox is highly contagious and virulent. As many as 30% of those infected could die as there is no known cure -- and if the hemorrhagic or flat smallpox variants were to be used the death rates would be much higher, 95-99%.
Currently available smallpox vaccines use modified live Vaccinia virus that are costly and time intensive in their application. As an indication, to vaccinate just a million people per day, using current methods and immunization process, would require about 35,000 medical teams as well as the infrastructure to support the initiative. Further, current vaccines are also not considered safe for use in certain segments of the population, especially those with skin diseases, immune disorders, HIV, and pregnant or lactating mothers. In addition, the FDA requires a "Black Box" (serious danger) warning on a large proportion of the currently available doses of smallpox vaccine due to concerns about occurrence of heart toxicity called acute myopericarditis in healthy individuals.
In early 2003, the U.S. government decided to vaccinate 500,000 civilian healthcare workers who would be responsible for the vaccination of the general population if necessary. By April 13, 2003, the Centers for Disease Control reported 86 potentially with serious side effects, including several deaths and several dozen cases of myocarditis -- consequently only just 32,644 healthcare workers volunteered to be vaccinated. Vaccine safety is of primary concern.
For smallpox vaccine to be available to the entire population in the event of an outbreak, MDM Group and AvaxisBio are targeting a greatly improved product and vaccination process. Both are clearly needed should such a threat materialize.
AvaxisBio Corporation was incorporated in the state of Delaware on November 8, 2004. Based on the Business Plan developed by Dr. Amir Maksyutov, senior technical director and inventor in cooperation with the US Department of State BII program (BioIndustry Initiative), AvaxisBio has attracted significant potential investment interest in the company. AvaxisBio is focused on commercializing the Maksyutov Antigenic Peptide technology platform, a method for designing vaccines that takes into account the genetic variability of pathogens that cause AIDS, Hepatitis C, and Influenza. BII enabled the commercialization of this platform through a strategic PCT (Patent Convention Treaty) filing after the early-stage discovery work was funded by BTEP (Biotechnology Engagement Program).
AvaxisBio has developed a computerized method that allows for selection of the specific regions within viral proteins that will cause a desirable immune effect against smallpox, while ruling out those regions which might cause autoimmune or other side effects. This method, based on original antigenic similarity matrix, takes into account small changes in the amino acid building block sequence of the protein regions and whether they do or do not affect the safety or efficacy of the vaccine component.
MDM Vice President, Ed Stephen, has indicated that the new vaccine is expected to be safe in all population segments as well as be effective against all strains of pox viruses by the nature of the component selection process that is proprietary to AvaxisBio.
Under the terms of the AvaxisBio agreement, MDM Group will fund certain ongoing expenses during a due diligence period, after which MDM will acquire a 50% interest in a joint company that will be newly-formed for the purpose of developing and testing smallpox vaccines, in exchange for $0.5 million of initial seed capital and other non-monetary contributions to support on-going research activities.
MDM Group's Biodefense Division is focused on discovery of and rapid development of vaccines and other countermeasures to support the Homeland Defense requirements of the United States government and its citizens as well as those in other countries.
MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries.
For further information see: http://www.mdmgroupinc.com/
MDM Group is featured on www.Homelanddefensestocks.com a global investment research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=AA2650AA782F2530
SOURCE: MDM Group, Inc
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Aerospace and Defense:Weapons
Agriculture:Livestock
Government:National
Government:Security (law enforcement, homeland etc)
Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials
ProfitScout
19 years ago
Smallpox Vaccine to Be Developed by MDM Group's Biodefense Division
SANTA CLARA, CA, Aug 04, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that its Biodefense Division is finalizing agreements to develop a novel vaccine for smallpox designed for safe public immunization to counter bioterrorism. Currently available smallpox vaccines use modified live vaccinia virus that are time intensive in their application. They are also not considered safe for use in certain segments of the population, especially those with skin diseases, immune disorders, HIV, and pregnant or lactating mothers. In addition, the FDA requires a "Black Box" (serious danger) warning on a large proportion of the currently available doses of smallpox vaccine due to concerns about occurrence of heart toxicity called acute myopericarditis in healthy individuals.
Smallpox is a top priority on the U.S. Centers for Disease Control bioterrorism threat list. Smallpox was declared eradicated in 1980 and the last outbreak in the U.S. was in 1949. Although the official repositories of the virus are maintained under high security in the United States and Russia, there is concern that terrorists may have access to smallpox virus that could be used as a bioweapon. If this happened, many people could become seriously ill as smallpox is highly contagious and virulent and as many as 30% of those infected could die as there is no known cure -- if the hemorrhagic or flat smallpox variants were to be used the death rates could be as great as 95-99%.
MDM Vice President, Ed Stephen, stated that the new vaccine is expected to be safe in all population segments as well as be effective against all strains of pox viruses by the nature of the proprietary component selection process. He further advised that the Company expects to announce further details of the project and agreements during the course of the coming week.
MDM Group's Biodefense Division is focused on discovery of and rapid development of vaccines and other countermeasures to support the Homeland Defense requirements of the United States government and its citizens as well as those in other countries.
MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries.
For further information see: http://www.mdmgroupinc.com
MDM Group is featured on www.Homelanddefensestocks.com a global investment research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=AA4DC40F2B9D7223
SOURCE: MDM Group, Inc
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Financial Services:Commercial and Investment Banking
Government:Security (law enforcement, homeland etc)
Medical and Healthcare:Health and Nutrition
Medical and Healthcare:Healthcare
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Trials
ProfitScout
19 years ago
MDM Group Advises of Its Oral Fluid Business Initiative Repositioning
SANTA CLARA, CA, Aug 01, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that the Company intends to proceed with the previously announced Collaboration Agreement with Sun Biomedical Laboratories, concentrating its business focus on the unique tests for illicit drugs that in the Company's opinion are positioned to become the industry standard, tests for clinical applications and also process and device technologies.
The Company further advises that it will not be proceeding with the Bamburgh Marrsh acquisition.
Oral fluid testing and/or diagnosis is rapidly being established as an extremely economic, efficient and non-invasive process that through the Company's technologies will be capable of delivering instant on the spot results as opposed to the far more expensive, invasive and delayed results of tests using urine or blood samples. As referenced within an Interview published by the Wall Street Journal last April 19: "A sample of saliva can have within it DNA, RNA, proteins, germs, viruses, fatty acids and a host of interesting molecules useful in disease detection... whatever is in the blood is probably also in saliva. It is, in most of the case, a reflection of our blood, it's a blood filtrate."
MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries. See: http://www.mdmgroupinc.com
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
For further information see: http://www.mdmgroupinc.com
MDM Group is featured on www.Homelanddefensestocks.com, a global investment research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=E9A64B200FC72ABC
SOURCE: MDM Group, Inc.
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Aerospace and Defense:Weapons
Government:Security (law enforcement, homeland etc)
Medical and Healthcare:Health and Nutrition
Medical and Healthcare:Surgery and Treatments
Professional Services:Consulting
bartermania
19 years ago
London Train Station Shooting Supports the Need for Less Lethal ShockRounds(TM)
SANTA CLARA, CA, Jul 25, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that the fatal shooting at Stockwell Station in London last Friday of a Brazilian electrician mistakenly thought to be a terrorist bomber suspect represents solid support for the future use of ShockRounds(TM) in such situations.
Had Jean Charles de Menezes been a terrorist, he could have been captured alive and been able to possibly provide valuable information. As is now apparent, having been innocent, his life may have been spared had the ShockRounds(TM) product been available for use.
When confronted with situations posing immediate threat to the public and infrastructure, our law enforcement agencies and special operatives have limited solutions available to them today. The continued escalation of terrorism and civil unrest on a global scale was what MDM Group identified as requiring an urgent solution that could be readily addressed through the ShockRounds(TM) opportunity.
ShockRounds(TM) are being developed and commercialized through MDM Group's Australian listed affiliate Harrington Group Limited (OTC: HGRLF) or Australian (ASX: HGR). See: www.hgrltd.com
ShockRounds(TM) are positioned as a major breakthrough in the munitions, military and law enforcement industries. This patent pending technology introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies.
Company President, Peter Boonen said: "Following the recent successful firing of the world's first "electric" and wireless 37mm ShockRounds(TM) rubber bullet round, we look forward to confirmation from Harrington Group of the commissioning of extended caliber opportunities for ShockRounds(TM) and the release of the first commercial product in Q1 of 2006. Quite obviously the sooner that Harrington Group gets the ShockRounds(TM) products to market, the sooner the much needed applications can be addressed."
MDM GROUP business interests focus on the Security, Biodefense, Law Enforcement and Homeland Security industries See: www.mdmgroupinc.com
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
MDM Group is featured on www.Homelanddefensestocks.com a research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=C4B735CF41C26432
SOURCE: MDM Group, Inc
Copyright 2005 Market Wire, All rights reserved.
ProfitScout
19 years ago
Major Drug Testing and Diagnostic Transaction Announced by MDM Group
MDM Group to Acquire Leading Oral Fluid Testing Technologies
SANTA CLARA, CA, Jul 21, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that it has entered into agreement with Sun Biomedical Laboratories, Inc. of New Jersey to acquire control of the world's leading oral fluid (saliva) testing technologies. The technologies comprise unique tests for illicit drugs, tests for clinical applications and also process and device technologies. Many of the tests have existing FDA clearances and along with the device technologies are protected by a series of issued patents.
MDM has entered into a Collaboration Agreement that has provision for the joint development and marketing of a unique product portfolio for a period of up to 18 years. MDM Group has negotiated a further eight-month option to acquire the Sun Biomedical business for $2.8 million through a share issue. Sun Biomedical, which was founded in 1993, currently has 12 employees and annual revenue of approximately $1.5 million.
Dr. Ming Sun, the founder of Sun Biomedical and a pioneer of oral fluid testing, stated: "We have explored many opportunities to expand our business so that we could be better positioned within the still young, but explosive, oral fluid diagnostic, screening and testing markets with our leading-edge and patent-protected technologies, and we envision MDM's Bamburgh Marrsh (See: www.bamburghmarrsh.com) collection, reader and overall evidential system to represent, in our view, the best available oral fluid test system available. It is clear that MDM's Bamburgh Marrsh is a perfect marriage partner for our business."
MDM Group CEO, Dr. Paul Slowey, PhD, stated: "Both as a founder of Bamburgh Marrsh and as the MDM Group CEO, I am absolutely delighted to be announcing our agreement with Sun Biomedical today. Having the opportunity to package exclusive and unique total testing and screening solutions within our corporate interests that can now incorporate the world's most advanced patent protected oral fluid testing technologies will most certainly contribute to giving us a market edge, as well as giving us the opportunity to become the world standard."
Oral fluid testing and/or diagnosis is rapidly being established as an extremely economic, efficient and non-invasive process that through the Company's technologies will be capable of delivering instant on the spot results as opposed to the far more expensive, invasive and delayed results of tests using urine or blood samples. As referenced within an Interview published by the Wall Street Journal last April 19: "A sample of saliva can have within it DNA, RNA, proteins, germs, viruses, fatty acids and a host of interesting molecules useful in disease detection.....whatever is in the blood is probably also in saliva. It is, in most of the case, a reflection of our blood, it's a blood filtrate."
Dr. Slowey adds: "Not only do we have major opportunities within the clinical disease identification markets, but we also are positioned as a major player in the Law Enforcement drug testing initiatives as well as having significant application in the biodefense, job screening, sports, gaming and similar markets."
MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries See: www.mdmgroupinc.com
For further information see: http://www.mdmgroupinc.com
MDM Group is featured on www.Homelanddefensestocks.com a global investment research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=0E695B7634101433
SOURCE: MDM Group, Inc.
Copyright 2005 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Alternative
Medical and Healthcare:Healthcare
Medical and Healthcare:Medical Devices
Medical and Healthcare:Nursing
Medical and Healthcare:Surgery and Treatments
Professional Services:Other Professional Services
ProfitScout
19 years ago
BiodefenseStocks.com Reports on Today's Technology and Countermeasures Working to Defend against Biowarfare and Bioterrorism; Homeland Security Department Elevates Bioterrorism to Higher Level of Priority
POINT ROBERTS, Wash., Jul 20, 2005 (BUSINESS WIRE) -- www.BiodefenseStocks.com (BS), and www.HomelandDefenseStocks.com (HDS), investor news portals for the Biodefense and Homeland Security sectors, report on today's technology and countermeasures working to defend against threats of bioterrorism through an exclusive article -- "Countermeasures against Bioterrorism and Biowarfare -- Are We Prepared?" Companies participating in the nation's biodefense efforts include CryoPort (Pink Sheets:CYRX), a manufacturer of a disposable cryogenic shipper for infectious materials; Hollis-Eden Pharmaceuticals, Inc. ( HEPH ), developer of the drug Neumune(TM) for treatment of Acute Radiation Syndrome (ARS); Aethlon Medical ( AEMD ), a developer of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body; Roaming Messenger ( RMSG ) an interactive messaging solution provider that enables the delivery of critical information; and MDM Group (Pink Sheets:MDDM), a developer of vaccines and screening solutions through their Biodefense Division.
BiodefenseStocks.com and HomelandDefenseStocks.com are investor and industry news portals for the biodefense and homeland security sector. The BS and HDS websites do not make recommendations, but offer unique, free information portals to research news, exclusive articles, interviews, investor conferences and a growing list of participating public companies in these sectors.
Report Excerpt: Countermeasures against Bioterrorism and Biowarfare -- Are We Prepared?
By Ann-Marie Fleming, www.BiodefenseStocks.com and www.HomelandDefenseStocks.com
July 2005
As the Homeland Security Department increases the priority level placed on bioterrorism, and the government pushes forward in the development of Project BioShield, the necessity for evolved and adaptive technology and methods to prevent and resolve such threats becomes a major focus for National Security and the industry at large.
Security Secretary Michael Chertoff recently presented the results of the Department of Homeland Security's Second Stage Review, which consists of an evaluation of the Department's operations, policies and structures. Subsequent to the release of the results of this review, a renewed sense of priority regarding the nation's ability to detect biological attacks became apparent. As Chertoff states, "We must also prepare for terror attacks of even greater consequence -- attacking transit systems with biological, radiological or chemical agents. We now have in place a network of bio-sensors, but we will accelerate the development and deployment of the next generation technology in bio-sensors to more quickly detect biological, radiological, and chemical attacks."
According to a report by Civitas Group, "In terms of the severity of consequences, the threat of a terrorist attack against the homeland involving a nuclear or biological weapon is the most worrisome scenario facing the United States today." With that said, the report revealed that the biological sensor market is still fairly undeveloped, but is experiencing significant forward progression as a result of the government's focus on such technology and biological threats. According to Mark Shaheen, a Principal at the Civitas Group, "The Second Stage Review indicates the intention of the Department to take a more significant role in biodefense, as evidenced by Chertoff's creation of a Chief Medical Officer who will be a direct, more senior official with responsibility for biodefense issues at the department; this is a positive sign."
Government programs such as Project Bioshield that was implemented to help spark participation in biodefense from the private sector, and in particular from biotechnology and pharmaceutical companies, has further emphasized the prioritization of the threat level associated with bioterrorism. However, Mr. Shaheen explains, while there is significant market potential for biosensors, the impact of BioShield is yet to be fully determined.
To Read the Full Report Click Here: http://www.BiodefenseStocks.com/BDS/News/Bioterror_Defense.asp
Participating Public Companies:
Hollis-Eden Pharmaceuticals, Inc. ( HEPH ), Aethlon Medical ( AEMD ), MDM Group (Pink Sheets:MDDM), CryoPort (Pink Sheets:CYRX), Roaming Messenger ( RMSG )
(HDS and BS are compensated for Featured companies on portals -- see disclaimer for details)
BiodefenseStocks.com includes public companies in the sector and industry information on Bioterrorism, Agriterrorism, Vaccines, Countermeasures to Bioterrorism, Biological & Chemical Detection, Emergency Response and Preparedness, Biological, Chemical, and Radiological News.
For a partial list of companies involved in Biodefense Click Here: http://www.biodefensestocks.com/BDS/Stock_List.asp
HomelandDefenseStocks.com includes a growing list of public companies in the sector. Click here for a partial list of companies involved in homeland defense and security technology and solutions in Airport Security, Biodefense, Biometrics, Defense, Internet Security, Integrated Security, Military, Border and Port Security. www.HomelandDefenseStocks.com/Companies/HomelandDefense/Stock_List.asp
Additional HDS Homeland Security Web Sites:
www.NationalHomelandSecurityKnowledgebase.com: including comprehensive Homeland Security information resources, Homeland Security news, Homeland Security marketplace, directories and a collection of links on Homeland Security related topics.
www.BorderAndPortSecurity.com
www.NonlethalStocks.com
The Insiders Corner with Michael Brush
Read the exclusive InvestorIdeas.com Feature "The Insiders Corner," a weekly feature by well-known financial writer and author Michael Brush. http://investorideas.com/insiderscorner/
Investor Incite Newsletter
InvestorIdeas.com free "Investor Incite" Newsletter consists of company and industry updates, investment research and developing trends in key areas such as Homeland Security, Renewable Energy, Nanotechnology and more.
TO SIGN UP, click here: www.InvestorIdeas.com/Resources/Newsletter.asp
Disclaimer: ECON Investor Relations Inc is the owner of the domains www.BiodefenseStocks.com and www.HomelandDefenseStocks.com. Our site does not make recommendations, but offers a unique information portal to investors to research news, articles, and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell any specific products or securities. All investments involve risk. Although we attempt to research thoroughly, we offer no guarantees as to the accuracy of any information presented. We encourage all investors to use our sites only as a resource to further their own research. All information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of ECON or its related web sites. The site is currently compensated for by its "featured companies." CryoPort, Inc.: Five Thousand Dollars per month. Aethlon Medical, Inc.: Three Thousand Dollars per month plus restricted shares equivalent to Five Thousand Dollars per month. MDM Group, Inc. pay an amount equal to approximately thirteen thousand five hundred. MDM Group Inc. shares per month for consulting services provide for both MDM Group Inc. and its subsidiary, Harrington Group Ltd. (HGR). Roaming Messenger, Inc. ( RMSG ) Three thousand dollars per month, plus three thousand dollars per month equivalent in shares. Featured Companies on HDS / BS current list of stocks. www.InvestorIdeas.com/About/Disclaimer.asp
SOURCE: ECON Investor Relations Inc.
ECON Investor Relations Inc.
Dawn Van Zant / Trevor Ruehs
Toll free: 800-665-0411
dvanzant@HomelandDefenseStocks.com
truehs@HomelandDefenseStocks.com
Copyright Business Wire 2005
ProfitScout
19 years ago
London Bombings Prompt MDM Group to Re-Release Global White Paper for Secure Global Travel
MDM White Paper Promotes MDM Technologies to Better Secure Travel Safety
SANTA CLARA, CA, Jul 19, 2005 (MARKET WIRE via COMTEX) -- MDM Group, Inc. (OTC: MDDM) advises that the London Bombings, tragic as they are, clearly demonstrate that not enough is being done to protect society against the now ever present threat of terrorism. A global uniform and secure system supporting identity confirmation and data-based profiling, as promoted in a MDM Group White Paper, may well have been able to identify the potential risk from likely perpetrators of this criminal action, well before the event.
MDM urges global authorities to urgently consider the security initiatives proposed within the White Paper and re-releases it as originally published shortly following the 9/11 tragedy in 2001. See. www.mdmgroupinc.com under "IT Security Division."
MDM Group owns and controls critical patented and proprietary technologies that can completely secure operating systems, networks and information that would need to be incorporated within sophisticated counter terrorism initiatives and that are able to totally secure and monitor control systems, identification and transactions including: user access, travel ticketing, financial and all other communications.
MDM President, Mr. Peter Boonen, stated: "A more concentrated, global and co-operative approach needs to be taken as this brand of terrorism will remain a threat for quite some time. Being driven by radical ideology the solutions will not be simple or expedient. The ongoing situations in Iraq and Israel are just two examples of how difficult it is to contain or end such fanatical and minority driven causes that continue to kill and maim innocent people. Being a target for the ideologically-driven fanatical minority of a 1.75 billion population base does not represent a situation that is capable of containment or being overcome within any reasonably predictable time frame."
MDM Group business interests focus on the Security, Biodefense, Law Enforcement and Homeland Security industries See: http://www.mdmgroupinc.com
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
For further information see: http://www.mdmgroupinc.com
MDM Group is featured on www.Homelanddefensestocks.com a research portal for defense and security.
Contact:
MDM Group, Inc.
Trevor Ruehs
866-894-3910
Contact via http://www.marketwire.com/mw/emailprcntct?id=BAFE4487310A2274
SOURCE: MDM Group, Inc.
ProfitScout
19 years ago
Perth firm makes electric rubber bullets
13:45 AEST Fri Jul 1 2005
AAP
Rioters could be in for a shock next time their behaviour gets out of hand, with an Australian company developing a rubber bullet which gives an electric shock.
Perth based Harrington Group is hoping its invention will help it crack what is known as the less lethal market, worth around $US500 million annually.
Less lethal law enforcement aims to control people without killing them.
It may be an occasional event in Australia but in other countries such as South Africa and Israel fatalities caused by police are a daily occurrence.
Harrington chief executive Marshall Couper said the market for electric rubber bullets was extensive.
"There are two to three riots around the world every day, whether they be prison riots in South America where you have massive overcrowding of prisons or there is a Ukrainian protest," he said.
"In Australia we tend not to fire bullets at teenagers that are just intoxicated but there is a call for them in certain circumstances, like the Sydney riots."
The electric rubber bullet builds on the rubber bullet, which is effective between 20 and 45 metres.
Any further than that and the bullet doesn't hurt.
The electric rubber bullet extends the range of effectiveness to 75 metres, delivering a shock on impact.
"The shock is not going to cause any damage, but it is like a heavy duty electric fence type of shock - you'll know you've been hit," Mr Couper said.
Extending the range of the bullet places law enforcers beyond the 55 metre mark, or the rock-throwing range, according to Mr Couper.
The Australian Stock Exchange-listed Harrington has just completed the first round of testing using US standard police issue guns.
The next stage is to trial the bullets with one division of the United States police volunteering, with the trial expected to be completed by the end of the year.
After that, rioters and boisterous party goers be warned.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Renee
10 years ago
Hot Features
Premium
